Serial 97611312
Live / Registered — Registered (as of 21 May 2024)
What this means for you
Registered since 21 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97611312
- Registration number
- 7392963
- Mark type
- Design / logo
- Filed
- 28 Sept 2022
- Published for opposition
- 23 Jan 2024
- Registered
- 21 May 2024
- Attorney of record
- Rajesh Fotedar
Goods and services
- Class 005 — Pharmaceuticals: Preparations for the relief of conditions caused by atopy for oral delivery and topical administration, namely, pharmaceutical preparations for developing tolerance to allergens; Preparations for the relief of allergies customized for a patient based on results from the patient's allergy tests, namely, pharmaceutical preparations for developing tolerance to allergens; Preparations for the relief of allergies customized for a patient based on results from the patient's at-home allergy tests, namely, pharmaceutical preparations for developing tolerance to allergens; Patient-customized preparations for the relief of allergies, namely, pharmaceutical preparations for developing tolerance to allergens; Patient-customized preparations for the relief of conditions caused by atopy for oral delivery and topical administration, namely, pharmaceutical preparations for developing tolerance to allergens; At-home allergy test kits comprised of medical diagnostic test patches for detecting allergen-specific immunoglobulin E (IgE) antibodies in blood samples in order to determine allergic reactions; Direct-to-consumer allergy test kits comprised of medical diagnostic test patches for detecting allergen-specific immunoglobulin E (IgE) antibodies in blood samples in order to determine allergic reactions for the purpose of obtaining information for customized preparations for the relief of allergies; Direct-to-consumer allergy test kits comprised of medical diagnostic test patches for detecting allergen-specific immunoglobulin E (IgE) antibodies in blood samples in order to determine allergic reactions for the purpose of obtaining information for customized pharmaceutical preparations for developing tolerance to allergens
- Class 044 — Medical, beauty and agricultural services: Telemedicine services and telemedicine treatment services for treatment of conditions caused by atopy, namely, for determining a treatment plan with prescription allergy medication in a formulation customized according to results of a patient's allergy test; Telemedicine services and telemedicine treatment services for treatment of conditions caused by atopy, namely, for determining a treatment plan with prescription allergy medication in a formulation customized according to results of a patient administered allergy test; Telemedicine services and telemedicine treatment services for treatment of conditions caused by atopy, namely, for determining a treatment plan with prescription allergy medication in a formulation customized according to results of a patient's at home allergy test; Telemedicine services and telemedicine treatment services for treatment of conditions caused by atopy, namely, for determining a treatment plan with prescription allergy medication in a formulation customized according to results of a patient's direct-to-consumer allergy test; Telemedicine services and telemedicine treatment services for treatment of conditions caused by atopy, namely, information regarding a treatment plan with customized pharmaceutical preparations for developing tolerance to allergens
Owner
- Nectar Life Sciences Inc., New York, NY, US
- Nectar Life Sciences Inc., New York, NY, US
- Nectar Life Sciences Inc., New York, NY, US
Prosecution history
- 21 May 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 18 Apr 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 17 Apr 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Mar 2024 — USE AMENDMENT FILED
- 12 Apr 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Mar 2024 — TEAS STATEMENT OF USE RECEIVED
- 19 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Jan 2024 — PUBLISHED FOR OPPOSITION
- 03 Jan 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Dec 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Dec 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Dec 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE